Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT SC versus IV efgartigimod in generalized myasthenia gravis
2020-004085-19Phase 3Completed
- Sponsor
- argenx
- Start
- Dec 2020
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of efgartigimod alfa and hyaluronidase in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoint: Percent reduction from baseline in total IgG levels at day 29. Started Dec 2020; status: completed.
02
Drugs
efgartigimod alfahyaluronidase
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-004085-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004085-19.